Nalaganje...

Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Guigao Lin, Kuo Zhang, Jinming Li
Format: Artigo
Jezik:Inglês
Izdano: MDPI AG 2015-11-01
Serija:International Journal of Molecular Sciences
Teme:
HBV
Online dostop:http://www.mdpi.com/1422-0067/16/11/25950
Oznake: Označite
Brez oznak, prvi označite!